Pharmacogenetics in the treatment of generalized anxiety disorder (GAD): a literature review

Authors

  • Betina Montanari Beltrame Faculdade de Farmácia, UFRGS. Av. Ipiranga, 2752 - Azenha, Porto Alegre - RS, 90610-000, Brasil.
  • Vandre Mateus Lima Curso de Farmacologia Clínica, Universidade Estácio de Sá. Av. Prof. Francisco Morato, 2343 - Butantã, São Paulo - SP, 05513-300, Brasil.

DOI:

https://doi.org/10.14450/2318-9312.v34.e3.a2022.pp214-221

Keywords:

anxiety, pharmacogenetics, genes.

Abstract

The inconsistency in each patient’s individual response to treatment with anxiolytic drugs is directly related to the genetic variations involved. This variability infl uences the therapeutic eff ects and can also dictate the adverse reactions of therapy; therefore, a dose that is benefi cial for one individual may be ineff ective and/or unsafe for another. The treatment of generalized anxiety is usually performed with antidepressant drugs, such as selective serotonin reuptake inhibitors (SSRI). Heritability patterns related to the metabolism processes of these drugs can infl uence the outcome of therapy. This work gathered literature data on the association of candidate genes with the response to the treatment of anxiety and analyzed the perspectives of  pharmacogenetics’s application in treating this pathology. The response to treatment with anxiolytics, such as SSRIs, depends on the variability of genes encoding proteins involved in the role of serotonin in the brain. Through studies, it was possible to detect these variations, and several showed the importance of pharmacogenetics. In addition, some of the genes related to SSRIs pharmacogenetics are already known (like CYP2D6, CYP2C19, CYP2C9), and this knowledge can be applied in clinical practice to personalize patients’ treatment. 

Downloads

Published

2022-09-30

How to Cite

Beltrame, B. M., & Lima, V. M. (2022). Pharmacogenetics in the treatment of generalized anxiety disorder (GAD): a literature review. Infarma - Pharmaceutical Sciences, 34(3), 214–221. https://doi.org/10.14450/2318-9312.v34.e3.a2022.pp214-221

Issue

Vol. 34 No. 3 (2022)

Section

Review Article

License

Authors who publish in this journal agree to the following terms:

 

  1. Authors retain the copyright and grant the journal the right of first publication, with the work simultaneously licensed under the Licença Creative Commons Attribution which allows the sharing of work with acknowledgment of authorship and initial publication in this journal.
  2. Authors are authorized to take additional contracts separately, for non-exclusive distribution of the version of the work published in this journal (e.g. publish in institutional repository or as a book chapter), with acknowledgment of authorship and initial publication in this journal.
  3. Authors are allowed and encouraged to publish and distribute their work online (e.g. in institutional repositories or on their personal page) at any point before or during the editorial process, as this can generate productive changes as well as increase the impact and Citation of published work (See O Efeito do Acesso Livre ).